Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OLEMA PHARMACEUTICALS, INC.

(OLMA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference

09/09/2021 | 07:31am EDT

SAN FRANCISCO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation of new preclinical data on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) being developed for the treatment of metastatic breast cancer and other women’s cancers, at the 1st JCA-AACR Precision Cancer Medicine International Conference being held virtually from September 10-12, 2021 (U.S.) and September 11-12 (Japan).

A virtual e-poster presentation titled, "Complete Estrogen Receptor (ER) Antagonism As An Optimal Approach for ER-Positive Breast Cancer Drug Development," along with a pre-recorded audio narration will be available on-demand on the conference website.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “anticipate,” “expect,” “intend,” “will,” “may,” “goal,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the development of OP-1250, including timelines related to data presentation, trial initiation and advancement, and enrollment, as well as the sufficiency of our financial resources. Because such statements deal with future events and are based on Olema’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, the risk that Olema’s ongoing or future clinical studies in humans may show that OP-1250 is not a tolerable and effective treatment for breast cancer and other risks and uncertainties affecting Olema, as well as those discussed in the section titled “Risk Factors” in Olema’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 to be filed on August 10, 2021 and future filings and reports that Olema makes from time to time with the United States Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com


Primary Logo


© GlobeNewswire 2021
All news about OLEMA PHARMACEUTICALS, INC.
09/30OLEMA PHARMACEUTICALS : Oncology Announces Trials in Progress Poster on OP-1250 at AACR-NC..
GL
09/30Olema Pharmaceuticals, Inc. Announces Trials in Progress Poster on OP-1250 at AACR-NCI-..
CI
09/16VC DAILY : Venture Capitalists Push Back Against Drug-Pricing Bill
DJ
09/09Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicin..
GL
08/30OLEMA PHARMACEUTICALS : Oncology to Present at Morgan Stanley 19th Annual Global Healthcar..
AQ
08/10OLEMA PHARMACEUTICALS : Oncology Reports Second Quarter 2021 Financial Results and Provide..
PU
08/10OLEMA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/10OLEMA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
08/10OLEMA PHARMACEUTICALS : Earnings Flash (OLMA) OLEMA ONCOLOGY Reports Q2 Loss $-0.42
MT
08/10Olema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Upd..
GL
More news
Analyst Recommendations on OLEMA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -68,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -17,8x
Yield 2021 -
Capitalization 1 212 M 1 212 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 37
Free-Float 90,4%
Chart OLEMA PHARMACEUTICALS, INC.
Duration : Period :
Olema Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OLEMA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 30,71 $
Average target price 55,75 $
Spread / Average Target 81,5%
EPS Revisions
Managers and Directors
Sean Bohen President, Chief Executive Officer & Director
Shane William Charles Kovacs Chief Operating & Financial Officer
Ian T. Clark Chairman
Pamela M. Klein Chief Medical Officer
Peter J. Kushner Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
OLEMA PHARMACEUTICALS, INC.-36.13%1 212
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414